Observations with Depo-Provera (medroxyprogesterone) in the management of renal tumours

I. Romics, D. Répássy

Research output: Contribution to journalArticle

Abstract

A total of 30 patients with renal tumours were started on Depo-Provera (medroxyprogesterone) in December 1981 and followed up for 17 to 44 months. The survivors were checked in July 1985. In 2 of the 13 metastasis-free patients deposits of lethal outcome had formed, survival time averaging 27 months. One of the 8 patients with local metastases had died of renal tumour, average survival time being 26 months. Among the 9 patients with distant metastases there are 2 with survival times of 42 and 44 months, respectively. The liver metastases confirmed by ultrasonography in the first, and in the vena cava in the second case at the time of surgery are no longer demonstrable. Survival time in the last-named group averages 14.5 months.

Original languageEnglish
Pages (from-to)49-54
Number of pages6
JournalInternational Urology and Nephrology
Volume19
Issue number1
DOIs
Publication statusPublished - Mar 1987

Fingerprint

Medroxyprogesterone
Medroxyprogesterone Acetate
Kidney
Neoplasm Metastasis
Survival
Neoplasms
Venae Cavae
Survivors
Ultrasonography
Liver

ASJC Scopus subject areas

  • Urology
  • Nephrology
  • Geriatrics and Gerontology

Cite this

Observations with Depo-Provera (medroxyprogesterone) in the management of renal tumours. / Romics, I.; Répássy, D.

In: International Urology and Nephrology, Vol. 19, No. 1, 03.1987, p. 49-54.

Research output: Contribution to journalArticle

@article{43f6d9d74abb41a485abefdc1e31a2d8,
title = "Observations with Depo-Provera (medroxyprogesterone) in the management of renal tumours",
abstract = "A total of 30 patients with renal tumours were started on Depo-Provera (medroxyprogesterone) in December 1981 and followed up for 17 to 44 months. The survivors were checked in July 1985. In 2 of the 13 metastasis-free patients deposits of lethal outcome had formed, survival time averaging 27 months. One of the 8 patients with local metastases had died of renal tumour, average survival time being 26 months. Among the 9 patients with distant metastases there are 2 with survival times of 42 and 44 months, respectively. The liver metastases confirmed by ultrasonography in the first, and in the vena cava in the second case at the time of surgery are no longer demonstrable. Survival time in the last-named group averages 14.5 months.",
author = "I. Romics and D. R{\'e}p{\'a}ssy",
year = "1987",
month = "3",
doi = "10.1007/BF02549677",
language = "English",
volume = "19",
pages = "49--54",
journal = "International Urology and Nephrology",
issn = "0301-1623",
publisher = "Springer Netherlands",
number = "1",

}

TY - JOUR

T1 - Observations with Depo-Provera (medroxyprogesterone) in the management of renal tumours

AU - Romics, I.

AU - Répássy, D.

PY - 1987/3

Y1 - 1987/3

N2 - A total of 30 patients with renal tumours were started on Depo-Provera (medroxyprogesterone) in December 1981 and followed up for 17 to 44 months. The survivors were checked in July 1985. In 2 of the 13 metastasis-free patients deposits of lethal outcome had formed, survival time averaging 27 months. One of the 8 patients with local metastases had died of renal tumour, average survival time being 26 months. Among the 9 patients with distant metastases there are 2 with survival times of 42 and 44 months, respectively. The liver metastases confirmed by ultrasonography in the first, and in the vena cava in the second case at the time of surgery are no longer demonstrable. Survival time in the last-named group averages 14.5 months.

AB - A total of 30 patients with renal tumours were started on Depo-Provera (medroxyprogesterone) in December 1981 and followed up for 17 to 44 months. The survivors were checked in July 1985. In 2 of the 13 metastasis-free patients deposits of lethal outcome had formed, survival time averaging 27 months. One of the 8 patients with local metastases had died of renal tumour, average survival time being 26 months. Among the 9 patients with distant metastases there are 2 with survival times of 42 and 44 months, respectively. The liver metastases confirmed by ultrasonography in the first, and in the vena cava in the second case at the time of surgery are no longer demonstrable. Survival time in the last-named group averages 14.5 months.

UR - http://www.scopus.com/inward/record.url?scp=0023112752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023112752&partnerID=8YFLogxK

U2 - 10.1007/BF02549677

DO - 10.1007/BF02549677

M3 - Article

VL - 19

SP - 49

EP - 54

JO - International Urology and Nephrology

JF - International Urology and Nephrology

SN - 0301-1623

IS - 1

ER -